RA Capital Nexus Fund III, L.P.
Director at Climb Bio, Inc. (CLYM) and others. 45 filings on Aeon since Sep 8, 2025.
Files forCLYMClimb Bio, Inc.SIONSionna Therapeutics, Inc.ARTVArtiva Biotherapeutics, Inc.SEPNSepterna, Inc.FRNMFreenome, Inc.PBLSParabilis Medicines, Inc.BCAXBicara Therapeutics Inc.MLYSMineralys Therapeutics, Inc.EVMNEvommune, Inc.SGPSpyGlass Pharma, Inc.
Alert me on this person
+8.7%
Return per buy, 1 monthS&P +2.0%
That is +6.7 points vs the S&P
Record
Same numbers as the leaderboard, once there are 3 buys with a result18
Decisions
6
Companies
+8.7%
Return
+2.0%
S&P, same days
+6.7
vs S&P
72%
Up
+6.0
After selling, 5 sales
Planned sales (Form 144) count toward nothing: not the record, not a decision, not a signal. A sale reported on a Form 4 is measured apart, in its own column. "After selling" is what the stock did after each sale against the S&P over the same days, sign flipped, so a positive number means the stock fell behind the market after the sale. Sales never count toward the record, a signal or a score.
Filings
on Aeon, newest first
One filing can name more than one person, so a filing can appear on more than one page. A filing marked "Planned sale" is a Form 144, which is notice of a sale the person means to make, not a trade, and it counts toward nothing here.
Loading the filings.